Headed by a strong pool of 550+ scientists and researchers, R & D is the key growth driver for Intas. Its constant quest for developing new products and technology has led breakthrough innovations in a wide spectrum of areas such as Oncology, Hormones & NDDS, apart from other generic products. Till date, Intas has filed 50+ patents on novel formulations, API polymorphs/processes & analytical methods to its credit.
Intas’ continuous R & D initiatives have strengthened its product basket with the delivery of niche and complex products. Intas is also actively involved in the development and commercialization of biologics, in adherence to the European and the US Regulatory guidelines. The company is also focused on the discovery and development of New Chemical Entities (NCEs) targeting cancer and neurodegenerative diseases such as bipolar disorder.
Pharmaceutical Formulation Development
Intas’ primary focus area in formulation development includes:
- Day 1 launch upon patent expiry
- New drug formulations for existing products for lifecycle management
- Niche Formulations with technology barrier
- Non-infringing formulations under Para-IV/ 505 b (2) categories for the launch of products in the US prior to the patent expiration
- New drug delivery platforms
Comments
Post a Comment